January 2015

Ceftriaxone-Resistant Salmonella enterica Serotype Typhimurium Sequence Type 313 from Kenyan Patients Is Associated with the blaCTX-M-15 Gene on a Novel IncHI2 Plasmid

Samuel Kariuki
*Kenya Medical Research Institute*

Chinyere Okoro
*Wellcome Trust Sanger Institute*

John Kiiru
*Kenya Medical Research Institute*

Samuel Njoroge
*Kenya Medical Research Institute*

Geoffrey Omuse
*Aga Khan University, geoffrey.omuse@aku.edu*

*See next page for additional authors*

Follow this and additional works at: [http://ecommons.aku.edu/eastafrica_fhs_mc_pathol](http://ecommons.aku.edu/eastafrica_fhs_mc_pathol)

Part of the [Pathology Commons](http://ecommons.aku.edu/eastafrica_fhs_mc_pathol)

**Recommended Citation**


Available at: [http://ecommons.aku.edu/eastafrica_fhs_mc_pathol/124](http://ecommons.aku.edu/eastafrica_fhs_mc_pathol/124)
Ceftriaxone-Resistant Salmonella enterica Serotype Typhimurium Sequence Type 313 from Kenyan Patients Is Associated with the bla<sup>CTX-M-15</sup> Gene on a Novel IncHI2 Plasmid

centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; Aga Khan University Hospital, Nairobi, Kenya; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom

Multidrug-resistant bacteria pose a major challenge to the clinical management of infections in resource-poor settings. Although nontyphoidal Salmonella (NTS) bacteria cause predominantly enteric self-limiting illness in developed countries, NTS is responsible for a huge burden of life-threatening bloodstream infections in sub-Saharan Africa. Here, we characterized nine S. Typhimurium isolates from an outbreak involving patients who initially failed to respond to ceftriaxone treatment at a referral hospital in Kenya. These Salmonella enterica serotype Typhimurium isolates were resistant to ampicillin, chloramphenicol, cefuroxime, ceftriaxone, aztreonam, cefepime, sulfamethoxazole–trimethoprim, and cefpodoxime. Resistance to β-lactams, including to ceftriaxone, was associated with carriage of a combination of bla<sup>CTX-M-15</sup>, bla<sup>OXA-1</sup>, and bla<sup>TEM-1</sup> genes. The genes encoding resistance to heavy-metal ions were borne on the novel IncHI2 plasmid pKST313, which also carried a pair of class 1 integrons. All nine isolates formed a single clade within S. Typhimurium ST313, the major clone of an ongoing invasive NTS epidemic in the region. This emerging ceftriaxone-resistant clone may pose a major challenge in the management of invasive NTS in sub-Saharan Africa.

It is estimated that nontyphoidal Salmonella (NTS) causes ~100 million cases of gastroenteritis every year, of which ~155,000 are fatal (1). Although NTS predominantly causes localized gut infections, invasive NTS (iNTS) infections may occur when the bacteria spread beyond the mucosa to reach normally sterile sites, such as the bloodstream, bones, joints, and the brain (2). A significant burden of iNTS cases are found in sub-Saharan Africa (3, 4), caused mainly by Salmonella enterica serotypes Typhimurium and Enteritidis (5, 6). Infections with these serotypes are associated with poor outcomes, including a high rate of mortality, especially among children less than 5 years of age and in HIV-infected adults who have low CD4 T-lymphocyte counts (7, 8). Due to an increasing prevalence of resistance to commonly available antibiotics, extended-spectrum cephalosporins and fluoroquinolones now are recommended for the management of iNTS (9). However, these alternative antimicrobials are less widely available and more expensive to use in resource-limited settings. Although resistance to first-line antimicrobials, such as ampicillin, chloramphenicol, and cotrimoxazole, is common among NTS from Kenya and elsewhere in sub-Saharan Africa, resistance to ceftriaxone and fluoroquinolones has been reported rarely.

Whole-genome sequence analysis of S. Typhimurium, isolated in a number of countries in sub-Saharan Africa, has identified a novel multilocus sequence type (MLST), ST313, which is responsible for an ongoing epidemic in the region (10). These ST313 S. Typhimurium strains fall into two related ST313 clades and encode multidrug resistance (MDR), in part on integrons associated with the invasion-associated plasmid pSLT. Here, we report the isolation and genomic characterization of ST313 S. Typhimurium isolates from patients seeking treatment in a tertiary-care and teaching hospital in Nairobi, Kenya, that exhibited resistance to ceftriaxone with or without combined resistance to fluoroquinolones.

MATERIALS AND METHODS

Patients and NTS strains. Adults and children reporting with fever to the Aga Khan University Hospital in Nairobi, Kenya, and referred for blood culture investigations between April 2009 and December 2011 were included in this study (Table 1). These patients were admitted with severe sepsis and failed treatment with routinely used antimicrobials, including ceftriaxone. Meropenem or imipenem was used to treat the patients by following Sanford guidelines (2012) on antimicrobial therapy (30).

Blood specimens from children and adults were inoculated into blood culture media and incubated in a Bactec 9050 culture system (Becton, Dickinson and Company). All positive blood cultures were subcultured onto sheep blood agar, Salmonella-Shigella agar (SSA), and MacConkey agar plates (Oxoid, Basingstoke, United Kingdom). In addition, fecal samples from patients who had diarrhea initially were enriched in selenite F broth and subcultured on MacConkey agar and SSA (Oxoid). Bacterial isolates were identified by biochemical tests using API 20E strips (bioMérieux, Basingstoke, United Kingdom) and serotyped using agglutinating antisera (Murex Diagnostics, Dartford, United Kingdom). S. Typhimurium isolates were stored at −70°C on Protect beads (Technical Service Consultants Ltd., Heywood, United Kingdom).

Received 13 January 2015 Returned for modification 18 February 2015 Accepted 6 March 2015 Accepted manuscript posted online 16 March 2015


Address correspondence to Samuel Kariuki, samkariuki2@gmail.com.

Copyright © 2015, Kariuki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.
doi:10.1128/AAC.00078-15
Susceptibility profiles of different specimen types and patient categories are detailed in Table 1.

<table>
<thead>
<tr>
<th>Isolate ID</th>
<th>Source</th>
<th>Patient age</th>
<th>Patient category</th>
<th>Date of isolation</th>
<th>Susceptibility profile</th>
<th>ESBL test</th>
</tr>
</thead>
<tbody>
<tr>
<td>1891</td>
<td>Stool</td>
<td>43 yr</td>
<td>Inpatient</td>
<td>April 2010</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8982</td>
<td>Urine</td>
<td>1 mo</td>
<td>Inpatient</td>
<td>May 2010</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8943</td>
<td>Stool</td>
<td>2 yr</td>
<td>Inpatient</td>
<td>February 2012</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8947</td>
<td>Stool</td>
<td>33 yr</td>
<td>Outpatient</td>
<td>October 2010</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8942</td>
<td>Blood</td>
<td>4 yr</td>
<td>Inpatient</td>
<td>June 2009</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8945</td>
<td>Stool</td>
<td>Adult (age not known)</td>
<td>Outpatient</td>
<td>July 2009</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8946</td>
<td>Stool</td>
<td>Child (age not known)</td>
<td>Outpatient</td>
<td>December 2011</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8944</td>
<td>Blood</td>
<td>2 yr</td>
<td>Inpatient</td>
<td>February 2012</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
<tr>
<td>8948</td>
<td>Stool</td>
<td>Child (age not known)</td>
<td>Outpatient</td>
<td>December 2011</td>
<td>S S R R R R R R R R R R R Positive</td>
<td></td>
</tr>
</tbody>
</table>

a Susceptibility profiles of isolates analyzed in this study. NAL, nalidixic acid; CIP, ciprofloxacin; CRO, ceftriaxone; AMP, ampicillin; CHL, chloramphenicol; SXT, sulfamethoxazole-trimethoprim; ESBL test, ESBL status confirmed using the double disc synergy method. R, resistant; S, susceptible.

Antimicrobial susceptibility testing. NTS isolates were tested for susceptibility to antimicrobials by a controlled disk diffusion technique on diagnostic sensitivity testing (DST) agar (Oxoid) plates. The antibiotic discs (all from Oxoid) contained ampicillin (10 μg), tetracycline (30 μg), ceftriaxone (15 μg), chloramphenicol (30 μg), gentamicin (10 μg), ciprofloxacin (5 μg), cefotaxime (30 μg), and nalidixic acid (10 μg). Escherichia coli ATCC 25922 was included to control for disc potency and quality of the culture media. Susceptibility tests were interpreted using the Clinical and Laboratory Standards Institute (CLSI) guidelines (11). In addition, MICs were performed with an automated bacteriology analyzer, Vitek Compact 2 (bioMérieux), using Gram-negative card GN26, which had the following antimicrobials that were clinically relevant to Salmonella spp.: ampicillin, ceftriaxone, ciprofloxacin, cefepime, trimethoprim-sulfamethoxazole, and meropenem. Cefpodoxime, cefotaxime, aztreonam, and cefazolin are not clinically relevant to management of iNTS infections but were used as extended-spectrum beta-lactamase (ESBL) markers. Double disk synergy tests for ESBL confirmation were performed using previously described methods (12). Current CLSI updates on interpretation of ciprofloxacin susceptibility cutoffs on Salmonella spp. were utilized when reporting susceptibility results of blood culture isolates to clinicians for management of patients.

Genomic DNA preparation. Bacteria for genomic analysis first were grown on Luria-Bertani (LB) medium (Oxoid) by inoculating a single isolated colony into broth, followed by incubation overnight at 37°C. The bacterial growth was pelleted by centrifugation, and whole-genome DNA was extracted using the Wizard genomic DNA kit (Promega, Southamp-ton, United Kingdom). Aliquots of 20 to 50 ng/μL of DNA from each isolate were submitted for whole-genome sequencing.

Library preparation and DNA sequencing. Multiplex libraries with 108-bp reads and a mean insert size of 272 bp were prepared as previously described (13). The cluster formation, primer hybridization, and sequencing reactions were performed using the Illumina HiSeq sequencer (LLGC, Middlesex, United Kingdom). The resulting short-read sequences were deposited in the European Nucleotide Archive; accession numbers for the whole genome are listed below. An average of 91.7% of each strain was mapped using SMALT with a mean depth of 118.6-fold coverage in mapped regions across all isolates, as previously described (14).

Phylogenetic analysis. Maximum-likelihood phylogenetic trees were constructed using RAxML v7.0.4 (14), with an alignment of all the concatenated variant sites from the nonrepetitive and nonrecombinant genome included in the analyses as previously described (14). The maximum-likelihood ratios then were calculated using the general time-reversible model with a gamma correction for site variation as the nucleotide substitution model. The likelihood test ratios were determined as previously described (10). The support for nodes on the trees was extracted using the FigTree package v1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/).

PacBio sequencing and assembly. Sequencing was performed using the PacBio template preparation kit (PacBio, Menlo Park, CA, USA) by following a modified version of the 20-kb template preparation using the BluePippin size selection system protocol to prepare size-selected libraries from 5 μg of sheared DNA. Further sequencing was performed using the magnetic bead collection protocol, a 20,000-bp insert size, stage start, and 180-min movies to set up the run protocol in RS Remote. In order to capture smaller-sized plasmids, the 5-kb template preparation protocol was applied. De novo assembly was performed using the standard SMRT Analysis (v. 2.0.2) pipeline.

Plasmid genome analyses. The plasmid map was annotated using DNAPlotter 10.2. The identity of genes of interest was confirmed using NCBI tools, including BLAST. Mutations were detected using the protein sequence alignment CLUSTALW program (15). The identification of beta-lactamase gene mutations at the amino acid level was determined by comparing the amino acid sequence of the sequenced enzyme to that of the wild-type enzyme published at http://www.lahey.org/studies/

Study ethical approval. Ethical approval for the study was obtained from the KEMRI Ethical Review Committee (SSC no. 2027).

Nucleotide sequence accession numbers. Accession numbers for the whole-genome short-read sequences for each of the isolates analyzed are the following: 8947, ERR387652; 8944, ERR387653; 8942, ERR387656; 8948, ERR387657; 8943, ERR387720; 8945, ERR387721; 8946, ERR387722; 5580, ERR304067; 5597, ERR304068; 5575, ERR304078; 5582, ERR304079; 5576, ERR304080; 5912, ERR304081; 5647, ERR304082; 5634, ERR304083; 5632, ERR304084; 5581, ERR304086; 5578, ERR304087; 5577, ERR304088; A130, ERR023781; 8891, ERR044726; 8892, ERR044727; D2358, FN424405; and SL1344, FQ312003. The nucleotide sequence data for the pSBLT and pKST313 plasmids were submitted to the National Center for Biotechnology Information Data Libraries (GenBank), and the sequences have been given accession numbers LN794247 and LN794248, respectively.

RESULTS

Antimicrobial susceptibility and ESBL testing. The antimicrobial resistance profiles of the nine NTS isolates were identical, regardless of the source. These isolates also were positive for ESBL production by double disc synergy and MIC testing but were susceptible to ciprofloxacin and meropenem. In addition, all isolates also were resistant to ampicillin, chloramphenicol, cefuroxime, ceftriaxone, cefotaxime, aztreonam, cefepime, and sulfamethoxazole-trimethoprim (Table 2).

The ESBL-producing NTS isolates are ST313. Whole-genome sequence analyses of the nine isolates confirmed they belonged to the same ST313 clade that has been isolated frequently in the sub-Saharan Africa region (16). Phylogenetic analyses based on whole-genome single-nucleotide polymorphisms (SNPs) assigned as
previously reported for ST313 (10) showed that these ESBL-producing strains fell into clade II and were highly related to the reference ST313 invasive isolate D23580 from Malawi, with a mean SNP difference of 39 (range, 31 to 70). A mean SNP difference between each pair of only 21 (range, 0 to 70) meant that the nine isolates were even more closely related to each other than to D23580 or any other representative S. Typhimurium lineages, including the closest Kenyan strains described from previous outbreaks (Fig. 1). Thus, these isolates potentially represent a clone circulating within the study population. In addition, our pairwise comparison also showed that seven of these isolates, 8942, 8944, 8947, 8943, 8945, 8946, and 8948, harbor minimal genome differences, represented by only a 1- or 2-SNP difference. The other two isolates, 8891 and 8892, occupy a different branch of the tree and were separated from the others by an average of 48 SNPs (range, 27 to 69) (Table 2). Overall, the low chromosomal SNP differences indicate a clonal outbreak within the study population, especially given the clustering away from the historical Kenyan ST313 isolates on the tree (Fig. 1).

We next analyzed these isolates for characteristic genomic markers that have been described for the ST313 lineages, including plasmids, phage repertoire, and antibiotic resistance genes. A pSLBT IncFII plasmid similar to the multidrug-resistant plasmid found in D23580 (6) was identified in all isolates (Fig. 2A, i and ii).

### Table 2 MICs of isolates analyzed

<table>
<thead>
<tr>
<th>Isolate ID</th>
<th>CIP (μg/ml)</th>
<th>AMP</th>
<th>SXT</th>
<th>CRO</th>
<th>CTX</th>
<th>MEM</th>
<th>FOX</th>
<th>CPD</th>
<th>FEP</th>
<th>ATM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1891</td>
<td>0.006</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;256</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>2</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8892</td>
<td>0.012</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;256</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>2</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8943</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8947</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8942</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8945</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8946</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8944</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>8948</td>
<td>&lt;0.25</td>
<td>&gt;32</td>
<td>&gt;320</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&lt;0.25</td>
<td>8</td>
<td>&gt;8</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
</tbody>
</table>

* MICs against selected antimicrobials. CIP, ciprofloxacin; AMP, ampicillin; SXT, sulfamethoxazole-trimethoprim; CRO, ceftriaxone; CTX, cefotaxime; MEM, meropenem; FOX, cefoxitin; CPD, cefpodoxime; FEP, cefepime; ATM, aztreonam.

![FIG 1 Phylogenetic relationships between isolates. Unrooted maximum-likelihood tree showing the relationship between isolates (pink polygon) and other Kenyan ST313 organisms isolated between 2003 and 2005 (10). D23580 (lineage II), A130 (lineage I), and the reference isolate SL1344 (ST19) are indicated on the tree. Scale bars represent the number of substitutions that have occurred on each branch. The inset in panel B represents associated metadata of the isolate arranged to reflect phylogenetic positioning.](image-url)
These isolates also contained a conserved repertoire of phages similar to that of D23580 (Fig. 2B). The pSLBT plasmid carried resistance determinants for aminoglycosides (aadA1), streptomycin (strA and strB), β-lactams (blaTEM-1), chloramphenicol (catA1), trimethoprim (dhfr1), and sulfonamides (sul1 and sul2). These resistance genes were located in a region containing a degenerate Tn21 transposon (Fig. 3).

**Carriage of IncHI2 plasmids among the ST313 isolates.** In addition to the pSLBT IncFII plasmid, the nine ESBL-producing ST313 isolates contained an ∼300-kb IncHI2 plasmid, which we designate pKST313 (for plasmid from the ST313 Kenyan strain). pKST313 encodes two class 1 integrons, various transposons, multiple insertion sequence (IS) elements, and multiple resistance cassettes (Fig. 4A and B). One region of the plasmid encodes resistance to heavy-metals ions, including mercury (mer and tni genes), tellurite (ter genes), arsenic (ars genes), and copper (cusS and pcoE genes). This region also contained tellurite utilization genes (tel genes). A second region harbors genes conferring resis-
tance to antimicrobials, including aminoglycosides (aadA1), streptomycin (strA and strB), β-lactams (blaTEM-1), chloramphenicol (catA1), trimethoprim (dfrA1), and sulfonamides (sul1 and sul2), the majority of which are within a class 1 integron. The third region (between trbN and traN) contained genes responsible for plasmid replication, pilus formations, and conjugation. The gene encoding DNA repair protein UvrD also was found adjacent to this region. This plasmid also contained multiple ISs that include IS\textit{Ecp1}, associated with \textit{bla}_{CTX-M-15}, the integron-associated IS\textit{26}, IS\textit{4321} and IS\textit{5075}, located near the mercury resistance region, IS\textit{6100}, and IS\textit{5}.

**Redundancy in antimicrobial resistance genes/cassettes.** These \textit{S. Typhimurium} ST313 isolates carried multiple genes/cassettes conferring resistance to the same class of antimicrobials. Such genes/cassettes included two copies of \textit{strA} and \textit{strB} (one pair in the pSLBT plasmid and the other in the pKST313 plasmid) conferring resistance to aminoglycosides. The \textit{catA1} gene (in the pSLBT plasmid) and both \textit{catA1} and \textit{catB3} cassettes (in the pKST313 plasmid) encode resistance to chloramphenicol. The isolates also carried a combination of \textit{aac(6’)-lb} and a single copy of \textit{aadA1} in each plasmid, all encoding resistance to aminoglycosides. All of the isolates had multiple copies of β-lactamases that included \textit{bla}_{TEM-1} in both plasmids, \textit{bla}_{OXA-1} (that is poorly inhibited by clavulanic acid), and \textit{bla}_{CTX-M-15} (in pKST313). The \textit{dfrA1} cassette conferring resistance to trimethoprim was found in pSLBT, while pKST313 carried another trimethoprim resistance gene, \textit{dfrA14}. The most redundant resistance sets of genes were those conferring resistance to sulfonamides, with pKST313 carrying both the \textit{sul1} and \textit{sul2} gene, while a second copy of \textit{sul2} was located on the pKST313 plasmid.

**DISCUSSION**

Although ceftriaxone-resistant \textit{S. Typhimurium} strains have been reported previously in other countries in Europe (16), Asia (17, 18), and the United States (19, 20), few data are available on this phenotype in sub-Saharan Africa. \textit{S. Typhimurium} ST313 is the dominant pathovariant of invasive NTS disease in immunocompromised adults and children in sub-Saharan Africa, and it is noteworthy that the acquisition of this new plasmid has occurred within this clonal population. We describe clonally related MDR \textit{S. Typhimurium} ST313 isolates from adults and children who reported to a referral hospital with fever, with or without diarrhea, and initially were treated with ceftriaxone and failed to respond. The spectrum of resistance in these isolates extends beyond the cephalosporins to include tetracyclines, chloramphenicol, and aminoglycosides. Although high MIC values for cotrimoxazole, cefotaxime, ceftriaxone, and aztreonam were recorded (Table 2), these isolates remained susceptible to carbapenems and fluoro-
quinolones. Locally, ceftriaxone has been the drug of choice for use against INTS that are resistant to commonly available antimicrobials. Interestingly, none of these isolates was found to contain a cephapymycin resistance gene, such as the bla_kpc_1 gene. These isolates also were resistant to co-amoxiclav but did not carry any known inhibitor resistance genes, such as those that encode inhibitor-resistant TEMs (IRTs). A possible explanation for these unexpected observations is that these strains carry multiple copies of bla genes, namely, blaOXA-1, blaTEM-1, and blaCTX-M-15 genes. The blaOXA-1 gene has been reported to confer resistance to inhibitor β-lactams; therefore, the spread of this gene may limit the utility of such agents (21). The blaCTX-M-15 gene detected in these isolates encodes the most robust CTX-M-type ESBLs described to date and has a wider hydrolytic capability against most cephalosporins, including ceftazidime, than other CTX-Ms. The blaCTX-M-15 gene was physically linked to the ISep1 element that has been implicated in the expression and transposition of this gene and has been linked to global dissemination in E. coli.

The NTS described in this study carried two plasmids that encode resistance to multiple antimicrobials. The pSLBT plasmid also harbored multiple virulence genes and integron-borne resistance determinants as previously described (6). However, the majority of resistance genes in these isolates were borne on pKST313, a significant portion of which is dedicated to antibiotic resistance and resistance to heavy-metal ions. This plasmid could play a critical role in the persistence of NTS and other bacteria in environments heavily contaminated with detergents, heavy metals, and other antimicrobials (22).

We found the Tn3 blaTEM-1-strB-strA-sul2 gene motif, which has been described as a promiscuous sequence that has the potential to spread to different types of plasmids. As reported in other studies, this gene motif was closely associated with IS26 and IS4321. The IS26-associated blaTEM-1-strB-strA-sul2 sequences have been reported on other plasmids, such as pHCM1 (23) and pAKU1 (24). Similar sequences also have been reported in other IncF plasmids, such as the 120-kb IncF plasmid isolated in Germany in 2005 (designated pRSB107) (25) and the IncF-like plasmid pU302L of S. Typhimurium G8430 (26).

Previous studies have indicated that bacteria bearing a combination of antimicrobial and heavy-metal resistance genes are released from poorly treated wastewater treatment plants (27, 28). It is important to note that pKST313 shares over 80% of resistance genes and (mobile) genetic elements with an IncH12 (pK29) plasmid found in some clinical Klebsiella pneumoniae strains, while the metal resistance region is similar to determinants found on plasmids in E. coli, Pseudomonas spp., and the soil bacteria Rhizobium spp. (29). These findings suggest that the novel plasmid originated from the environment and is a hybrid of different plasmids, IS elements, and transposons brought together through recombination. Comparative analysis indicates that IS26 detected in multiple copies can act as a recombination junction between plasmid ancestors that can lead to the emergence of new phenotypes.

In conclusion, we observed in Kenya the emergence of ceftriaxone-resistant S. Typhimurium ST313 that has been associated with an epidemic of invasive bacterial disease. This resistance and MDR phenotype are borne in part on the pKST313 plasmid, which contains integrative elements with the potential to rapidly disseminate. These data highlight the threat of an epidemic shaped by this new MDR phenotype.

ACKNOWLEDGMENTS
We thank the Director, KEMRI, for permission to publish.

The work was supported in part by The Wellcome Trust. S.K. is supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under award number 1R01AI099525.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES


